Clinical trial · Interventional
Multidisciplinary Approach to Fatigue
Pilot Project for the Implementation of an Integrated Multidisciplinary Follow-up for Young Patients With Breast Cancer or Germ Cell Tumor
NCT05502224CI-TRIAL-00062057recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective longitudinal, single-center, non-randomized study for the implementation of an integrated multidisciplinary fatigue follow-up for young patients with breast cancer or germ cell tumour
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Germ Cell Tumor | Germ Cell Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ergospirometry | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Specific fatigue management program
- interventionNames
- Other: Ergospirometry
Primary outcomes (1)
- measure
- Evaluate the feasibility of the specific fatigue management program
- timeFrame
- Through study completion, an average of 4 years
- description
- Rate of participation The program will be considered feasible for a given patient if he/she participates in a minimum of 70% of the 70% of the sessions/activities defined in their particular program
Secondary outcomes (1)
- measure
- The measurement of the evolution of the intensity of residual fatigue in the months following acute cancer treatment(s) before and after the specific fatigue management program
- timeFrame
- At the time of multidisciplinary screening and at 1, 3, 6, 12 and 18 months after completion of the specific fatigue management program.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 39 Years
Show eligibility criteria text
Inclusion Criteria: * Age between 18 and 39 years at the time of signing the informed consent * Patient who speaks and understands French * Signed study informed consent form obtained prior to any study related procedures * At minimum, a moderate (\>3) fatigue level according to the Standard Rating Scale (NRS) 1 month after completion of acute treatment; as measured at the Survivorship of the standard program * Patient with either: curative breast cancer (AJCC stage I-II-III) or a germ cell tumor Exclusion Criteria: * Refusal to participate in the study * Patient having chosen to participate in another psychosocial intervention study for the duration of the study. * Patients with AJCC stage IV breast cancer
References
Publications (0)
Data not yet available
No reference posted for this study.